Floatz logo

xt-150

Neuropathic Pain

Xalud Therapeutics, Inc.Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

53 Active assets in the Neuropathic Pain cohort.

Asset / SponsorPhaseRating
Pregabalin
Ziauddin University
Phase 4A
Bxcl501
Universidad Juárez Autónoma de Tabasco
Phase 4BBB
Capsaicin
NeurogesX
Phase 3BBB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Ataturk University
Phase 4BBB
MIDAZOLAM
Minia University
Phase 4BBB

View all 50 →

Same molecule, other indications

xt-150 is also rated in:

amyotrophic lateral sclerosisDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →